高级检索
    杨春丽, 邹立群. ECHELON-2研究: Brentuximab Vedotin联合CHP方案一线治疗CD30表达阳性的外周T细胞淋巴瘤的疗效分析[J]. 循证医学, 2020, 20(2): 85-88. DOI: 10.12019/j.issn.1671-5144.2020.02.006
    引用本文: 杨春丽, 邹立群. ECHELON-2研究: Brentuximab Vedotin联合CHP方案一线治疗CD30表达阳性的外周T细胞淋巴瘤的疗效分析[J]. 循证医学, 2020, 20(2): 85-88. DOI: 10.12019/j.issn.1671-5144.2020.02.006
    shu
    Reviewers: YANG Chun-li, ZOU Li-qun. ECHELON-2 Study: Curative Effect Analysis of Brentuximab Vedotin with CHP Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma[J]. Journal of Evidence-Based Medicine, 2020, 20(2): 85-88. DOI: 10.12019/j.issn.1671-5144.2020.02.006
    Citation: Reviewers: YANG Chun-li, ZOU Li-qun. ECHELON-2 Study: Curative Effect Analysis of Brentuximab Vedotin with CHP Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma[J]. Journal of Evidence-Based Medicine, 2020, 20(2): 85-88. DOI: 10.12019/j.issn.1671-5144.2020.02.006
    shu

    ECHELON-2研究: Brentuximab Vedotin联合CHP方案一线治疗CD30表达阳性的外周T细胞淋巴瘤的疗效分析

    ECHELON-2 Study: Curative Effect Analysis of Brentuximab Vedotin with CHP Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma

      摘要
      • HTML全文
      • 参考文献(8)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回